# Aligos Therapeutics, Inc.: financial statements, quarterly

ALGS · Nasdaq · CIK 1799448 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/algs.md) · [Financials](/companies/algs/financials.md) · [Filings](/companies/algs/filings.md) · [Insiders](/companies/algs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/algs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.1](/filings/0000950170-24-122371.md) | [0.7 d](/filings/0000950170-25-035929.md) | [0.7](/filings/0000950170-25-063983.md) | [1.1](/filings/0000950170-25-104042.md) | [1.3](/filings/0001193125-25-268203.md) | [0.6 d](/filings/0001193125-26-092614.md) | [0.3](/filings/0001193125-26-212001.md) | [1.0](/filings/0001193125-26-336851.md) | [0.7](/filings/0001193125-25-268203.md) | [0.2 d](/filings/0001193125-26-092614.md) | [2.8](/filings/0001193125-26-212001.md) | [0.0](/filings/0001193125-26-336851.md) |
| Research and development | $m | [15.9](/filings/0000950170-24-122371.md) | [22.3 d](/filings/0000950170-25-035929.md) | [16.4](/filings/0000950170-25-063983.md) | [21.1](/filings/0000950170-25-104042.md) | [16.8](/filings/0001193125-25-268203.md) | [16.0 d](/filings/0001193125-26-092614.md) | [14.5](/filings/0001193125-26-212001.md) | [14.0](/filings/0001193125-26-336851.md) | [23.9](/filings/0001193125-25-268203.md) | [17.0 d](/filings/0001193125-26-092614.md) | [23.4](/filings/0001193125-26-212001.md) | [24.1](/filings/0001193125-26-336851.md) |
| Operating income | $m | [(19.1)](/filings/0000950170-24-122371.md) | [(26.0) d](/filings/0000950170-25-035929.md) | [(22.0)](/filings/0000950170-25-063983.md) | [(26.4)](/filings/0000950170-25-104042.md) | [(20.1)](/filings/0001193125-25-268203.md) | [(20.6) d](/filings/0001193125-26-092614.md) | [(19.2)](/filings/0001193125-26-212001.md) | [(18.6)](/filings/0001193125-26-336851.md) | [(28.4)](/filings/0001193125-25-268203.md) | [(21.8) d](/filings/0001193125-26-092614.md) | [(26.9)](/filings/0001193125-26-212001.md) | [(1.9)](/filings/0001193125-26-336851.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-122371.md) | [(0.0) d](/filings/0000950170-25-035929.md) | [0.0](/filings/0000950170-25-063983.md) | [0.2](/filings/0000950170-25-104042.md) | [0.1](/filings/0001193125-25-268203.md) | [0.0 d](/filings/0001193125-26-092614.md) | [0.0](/filings/0001193125-26-212001.md) | [0.2](/filings/0001193125-26-336851.md) | [0.1](/filings/0001193125-25-268203.md) | [0.0 d](/filings/0001193125-26-092614.md) | [0.3](/filings/0001193125-26-212001.md) | [2.8](/filings/0001193125-26-336851.md) |
| Net income | $m | [(18.0)](/filings/0000950170-24-122371.md) | [(27.9) d](/filings/0000950170-25-035929.md) | [(34.9)](/filings/0001193125-25-268203.md) | [5.1](/filings/0001193125-25-268203.md) | [(19.3)](/filings/0001193125-25-268203.md) | [(82.2) d](/filings/0001193125-26-092614.md) | [43.1](/filings/0001193125-26-336851.md) | [(15.9)](/filings/0001193125-26-336851.md) | [(31.5)](/filings/0001193125-25-268203.md) | [(19.9) d](/filings/0001193125-26-092614.md) | [(23.0)](/filings/0001193125-26-336851.md) | [(1.5)](/filings/0001193125-26-336851.md) |
| Diluted EPS | $ per share | [(10.37)](/filings/0000950170-24-122371.md) | not reported | [(5.58)](/filings/0000950170-25-063983.md) | [0.81](/filings/0000950170-25-104042.md) | [(3.07)](/filings/0001193125-25-268203.md) | not reported | [(2.11)](/filings/0001193125-26-212001.md) | [(1.53)](/filings/0001193125-26-336851.md) | [(3.04)](/filings/0001193125-25-268203.md) | not reported | [(2.21)](/filings/0001193125-26-212001.md) | [(0.14)](/filings/0001193125-26-336851.md) |
| Basic EPS | $ per share | [(10.37)](/filings/0000950170-24-122371.md) | not reported | [(5.58)](/filings/0000950170-25-063983.md) | [0.81](/filings/0000950170-25-104042.md) | [(3.07)](/filings/0001193125-25-268203.md) | not reported | [5.12](/filings/0001193125-26-212001.md) | [(1.53)](/filings/0001193125-26-336851.md) | [(3.04)](/filings/0001193125-25-268203.md) | not reported | [(2.21)](/filings/0001193125-26-212001.md) | [(0.14)](/filings/0001193125-26-336851.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [70.4](/filings/0000950170-24-122371.md) | [136](/filings/0000950170-25-035929.md) | [24.2](/filings/0000950170-24-054497.md) | [45.1](/filings/0000950170-24-091828.md) | [35.3](/filings/0000950170-24-122371.md) | [37.0](/filings/0001193125-26-092614.md) | [73.8](/filings/0000950170-25-063983.md) | [18.7](/filings/0000950170-25-104042.md) | [41.9](/filings/0001193125-25-268203.md) | [18.3](/filings/0001193125-26-336851.md) | [30.0](/filings/0001193125-26-212001.md) | [30.4](/filings/0001193125-26-336851.md) |
| Current assets | $m | [74.6](/filings/0000950170-23-058256.md) | [141](/filings/0000950170-25-035929.md) | [118](/filings/0000950170-24-054497.md) | [99.6](/filings/0000950170-24-091828.md) | [79.8](/filings/0000950170-24-122371.md) | [62.1](/filings/0001193125-26-092614.md) | [143](/filings/0000950170-25-063983.md) | [128](/filings/0000950170-25-104042.md) | [103](/filings/0001193125-25-268203.md) | [82.9](/filings/0001193125-26-336851.md) | [59.6](/filings/0001193125-26-212001.md) | [62.1](/filings/0001193125-26-336851.md) |
| Total assets | $m | [85.9](/filings/0000950170-23-058256.md) | [152](/filings/0000950170-25-035929.md) | [128](/filings/0000950170-24-054497.md) | [109](/filings/0000950170-24-091828.md) | [88.4](/filings/0000950170-24-122371.md) | [70.1](/filings/0001193125-26-092614.md) | [151](/filings/0000950170-25-063983.md) | [135](/filings/0000950170-25-104042.md) | [110](/filings/0001193125-25-268203.md) | [88.5](/filings/0001193125-26-336851.md) | [64.6](/filings/0001193125-26-212001.md) | [66.3](/filings/0001193125-26-336851.md) |
| Current liabilities | $m | [22.5](/filings/0000950170-23-058256.md) | [23.9](/filings/0000950170-25-035929.md) | [18.9](/filings/0000950170-24-054497.md) | [23.6](/filings/0000950170-24-091828.md) | [21.0](/filings/0000950170-24-122371.md) | [21.7](/filings/0001193125-26-092614.md) | [18.9](/filings/0000950170-25-063983.md) | [20.3](/filings/0000950170-25-104042.md) | [22.0](/filings/0001193125-25-268203.md) | [21.2](/filings/0001193125-26-336851.md) | [23.3](/filings/0001193125-26-212001.md) | [28.3](/filings/0001193125-26-336851.md) |
| Total liabilities | $m | [31.0](/filings/0000950170-23-058256.md) | [59.4](/filings/0000950170-25-035929.md) | [68.1](/filings/0000950170-24-054497.md) | [41.6](/filings/0000950170-24-091828.md) | [38.3](/filings/0000950170-24-122371.md) | [99.1](/filings/0001193125-26-092614.md) | [34.3](/filings/0000950170-25-063983.md) | [32.8](/filings/0000950170-25-104042.md) | [37.9](/filings/0001193125-25-268203.md) | [35.0](/filings/0001193125-26-336851.md) | [32.8](/filings/0001193125-26-212001.md) | [34.4](/filings/0001193125-26-336851.md) |
| Shareholders' equity | $m | [54.8](/filings/0000950170-24-122371.md) | [92.1](/filings/0001193125-26-092614.md) | [59.8](/filings/0001193125-25-268203.md) | [67.2](/filings/0001193125-25-268203.md) | [50.1](/filings/0001193125-25-268203.md) | [(29.0)](/filings/0001193125-26-336851.md) | [116](/filings/0001193125-26-336851.md) | [102](/filings/0001193125-26-336851.md) | [71.8](/filings/0001193125-25-268203.md) | [53.5](/filings/0001193125-26-336851.md) | [31.8](/filings/0001193125-26-336851.md) | [31.9](/filings/0001193125-26-336851.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(20.3) d](/filings/0000950170-24-122371.md) | [(22.7) d](/filings/0000950170-25-035929.md) | [(22.7)](/filings/0000950170-25-063983.md) | [(19.5) d](/filings/0000950170-25-104042.md) | [(20.1) d](/filings/0001193125-25-268203.md) | [(18.4) d](/filings/0001193125-26-092614.md) | [(20.9)](/filings/0001193125-26-212001.md) | [(15.5) d](/filings/0001193125-26-336851.md) | [(24.3) d](/filings/0001193125-25-268203.md) | [(21.7) d](/filings/0001193125-26-092614.md) | [(23.1)](/filings/0001193125-26-212001.md) | [(25.0) d](/filings/0001193125-26-336851.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [42.8](/filings/0000950170-23-058256.md) | [42.9](/filings/0000950170-24-054497.md) | [43.2](/filings/0000950170-24-091828.md) | [1.7](/filings/0000950170-24-122371.md) | [6.2](/filings/0000950170-25-063983.md) | [6.3](/filings/0000950170-25-104042.md) | [6.3](/filings/0001193125-25-268203.md) | [8.7](/filings/0001193125-26-212001.md) | [10.4](/filings/0001193125-26-336851.md) | [10.4](/filings/0001193125-25-268203.md) | [10.4](/filings/0001193125-26-212001.md) | [10.4](/filings/0001193125-26-336851.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,608,792 at 2021-08-04, from the cover of the [10-Q filed 2021-08-05](/filings/0001564590-21-041653.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.